BiotechTube

Naltrexone

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Methamphetamine Dependence

Conditions

Methamphetamine Dependence

Trial Timeline

Sep 1, 2009 → Sep 1, 2012

NCT ID
NCT00984360

About Naltrexone

Naltrexone is a phase 2 stage product being developed by Pacific Biosciences for Methamphetamine Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00984360. Target conditions include Methamphetamine Dependence.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00984360Phase 2Completed

Competing Products

6 competing products in Methamphetamine Dependence

See all competitors
ProductCompanyStageHype Score
CPP-109 vigabatrin + Matching PlaceboCatalyst PharmaceuticalsPhase 2
47
A single oral 5 mg of duterium labeled methamphetaminePacific BiosciencesApproved
77
Dextroamphetamine + PlaceboPacific BiosciencesPhase 2
44
modafinilPacific BiosciencesPhase 2
44
ModafinilPacific BiosciencesPhase 2
44
Ibudilast 20mg + Ibudilast 50mg + Placebo oral tabletMediciNovaPhase 1
25

Other Products from Pacific Biosciences

pantoprazole + bismuth + metronidazole + tetracyclineApproved
77
EmtricitabineApproved
77
A single oral 5 mg of duterium labeled methamphetamineApproved
77
RamiprilApproved
77
Emtricitabine plus adefovir dipivoxilApproved
77